(Q34396876)

English

Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

P Brossard

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

M Scherz

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A Halabi

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

H Maatouk

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A Krause

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

J Dingemanse

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

9 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

179-188

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Fingolimod for relapsing multiple sclerosis: an update.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Dissecting the role of the S1P/S1PR axis in health and disease.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Lysophospholipid receptors: signaling and biology

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Sphingosine-1-phosphate receptors: zooming in on ligand-induced intracellular trafficking and its functional implications.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Sphingosine kinase and sphingosine 1-phosphate in asthma

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Factors predisposing to the development of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Use of a biomarker in exposure-response analysis to support dose selection for fingolimod

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.244

21 January 2018

Identifiers

10.1002/JCPH.244

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34396876&oldid=2143922115"